Synergy of Polydopamine Nanovaccine and Endostar Alginate Hydrogel for Improving Antitumor Immune Responses Against Colon Tumor
Authors:
Open Access
- 12 October 2022
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 17, 4791-4805
Abstract
Background: Tumor immunotherapy, a novel type of therapeutic treatment, has a wide range of applications with potentially prolonged benefits. However, current immunotherapy has a low overall response rate in treating a variety of tumors. Combination of immunotherapy with other therapies can improve the therapeutic response rates. The purpose of this work was to explore the potential of anti-angiogenic treatment in combination with tumor cell lysate loaded polydopamine nanoparticle vaccine as a therapeutic strategy for colon tumor. Methods: We grafted tumor cell lysate onto polydopamine nanoparticles as nano-vaccine (TCLN) and fabricated alginate hydrogel loaded with Endostar (EH), then detected characteristics of EH and TCLN. We also estimated the cytotoxicity of EH/TCLN in vitro. In the tumor-bearing mouse model, we evaluated the antitumor effect of EH/TCLN treatment, and developed the animal survival study. After performing the EH/TCLN treatment, we also analyzed T cells and DCs using flow cytometry, and determined T cell responses and tumor microenvironmental cytokines. At last, we assessed the effect of the EH/TCLN treatment on anti-angiogenesis further. Results: When applied in combination with TCLN in MC-38 tumor-bearing mice, EH/TCLN significantly suppressed tumor growth with more than half of the mice showing tumor regression. In addition, EH/TCLN treatment resulted in noticeable changes in the tumor microenvironment. As compared with the control group, EH/TCLN treatment led to significantly reduced tumor angiogenesis and expression of tumor microenvironment-related cytokines (TMCs), increased proportion of CD8+ T cells in the spleen, lymph node and tumor, elevated activity of cytotoxic T lymphocytes (CTLs) and tumor cell apoptosis. Conclusion: The present study demonstrated that the EH/TCLN treatment effectively created a favorable immune microenvironment for the induction of antitumor immunity and improved antitumor immune responses. Graphical Abstract:Keywords
This publication has 50 references indexed in Scilit:
- Regulatory T cells inhibit acute IFN-γ synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10Proceedings of the National Academy of Sciences, 2011
- The parallel lives of angiogenesis and immunosuppression: cancer and other talesNature Reviews Immunology, 2011
- Gene Therapy with Recombinant Adenovirus Encoding Endostatin Encapsulated in Cationic Liposome in Coxsackievirus and Adenovirus Receptor-Deficient Colon Carcinoma Murine ModelsHuman Gene Therapy, 2011
- Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriersInternational Journal of Nanomedicine, 2011
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapyCancer and Metastasis Reviews, 2011
- Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma modelProceedings of the National Academy of Sciences, 2010
- Sustained delivery of endostatin improves the efficacy of therapy in Lewis lung cancer modelJournal of Controlled Release, 2009
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Antiangiogenic Activity of the Cleaved Conformation of the Serpin AntithrombinScience, 1999
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971